IFNG and neoplasm: Lack of tumor infiltration by immune cells, which results in low IFNγ signature, constitutes one of the main mechanisms of resistance to ICB therapies (2, 5–7), and tumor-intrinsic oncogenic signaling pathways could drive immune cell exclusion from the tumor microenvironment (8–10).